Back to News
Market Impact: 0.25
Wells Fargo Upgrades Editas Medicine to Overweight from Equal-Weight
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
On October 8, 2026, Wells Fargo upgraded its outlook on Editas Medicine from Equal-Weight to Overweight. The article provides no price target, rationale, or share-price reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
EDIT0.50
More News
- Wall Street sees buying opportunity in banks as shares tank ahead of earnings
- Stifel cuts Targa Resources stock price target on capex outlook
- Cramer’s week ahead: Earnings kick off as banks and chipmakers face big tests
- What's behind the recovery rally in tech stocks — plus, Elon Musk's very good week
- Earnings season kicks into high gear as big banks report next week. Here's what's ahead
- Milos Maricic: listen for the AI number on next week’s bank calls